BRCA2 and pachyonychia congenita: BRCA1/2 mutations also affect the response to treatment; metastatic PC patients with germline BRCA2 mutations became resistant to the androgen deprivation therapy faster than non-carriers (13.2 vs. 28 months), showing a halved CSS [9,19,23,53,56,92,188].